

NEW AUSTRALIAN HUMAN PEMPHIGUS VULGARIS TRIAL RECRUITING AT ST GEORGES HOSPITAL KOGARAH

Instead of treating with standard therapy of corticosteroids and corticosteroid-sparing agents, this open-label cohort trial investigates a corticosteroid-free regimen to induce remission in newly diagnosed patients, and those relapsing on minimal treatment*.

The trial consists of 12 weeks therapy of PRN1008 tablets, twice a day, and 12 weeks follow up. Participants may also benefit from the close observation and specialist care at the trial center.


The experimental treatment is an oral Bruton's Tyrosine Kinase (BTK) inhibitor. In an outpatient trial in the USA of companion dogs with new onset, naturally occurring pemphigus foliaceus, a similar BTK molecule (PRN473) showed rapid clinical efficacy as a monotherapy in 7/7 cases (PDAI skin score figure).

Contact: 0422581459/ 0405643210

* Minimal treatment defined as <10mg prednisolone ± corticosteroid sparing agent
Protocol PRN1008-005



Baseline paw inflammation



Paws normal at 28 days

